RHOEN-KLINIKUM AG (RHK.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:RHK - DE0007042301 - Common Stock
12.9 EUR
+0.1 (+0.78%)
We assign a fundamental rating of 5 out of 10 to RHK. RHK was compared to 32 industry peers in the Health Care Providers & Services industry. While RHK has a great health rating, its profitability is only average at the moment. RHK is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year RHK was profitable.
RHK had a positive operating cash flow in the past year.
Each year in the past 5 years RHK has been profitable.
In the past 5 years RHK always reported a positive cash flow from operatings.
1.2 Ratios
The Return On Assets of RHK (2.02%) is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of 2.90%, RHK is doing worse than 62.50% of the companies in the same industry.
RHK has a Return On Invested Capital of 2.67%. This is in the lower half of the industry: RHK underperforms 71.88% of its industry peers.
The Average Return On Invested Capital over the past 3 years for RHK is below the industry average of 7.02%.
The 3 year average ROIC (2.34%) for RHK is below the current ROIC(2.67%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.02% | ||
| ROE | 2.9% | ||
| ROIC | 2.67% |
ROA(3y)2%
ROA(5y)1.56%
ROE(3y)2.83%
ROE(5y)2.2%
ROIC(3y)2.34%
ROIC(5y)2.01%
1.3 Margins
With a Profit Margin value of 2.28%, RHK perfoms like the industry average, outperforming 50.00% of the companies in the same industry.
RHK's Profit Margin has declined in the last couple of years.
The Operating Margin of RHK (2.86%) is worse than 62.50% of its industry peers.
In the last couple of years the Operating Margin of RHK has declined.
RHK's Gross Margin of 66.81% is fine compared to the rest of the industry. RHK outperforms 75.00% of its industry peers.
In the last couple of years the Gross Margin of RHK has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 2.86% | ||
| PM (TTM) | 2.28% | ||
| GM | 66.81% |
OM growth 3Y11.39%
OM growth 5Y-7.03%
PM growth 3Y10.42%
PM growth 5Y-3.92%
GM growth 3Y-1.4%
GM growth 5Y-0.67%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), RHK is destroying value.
Compared to 1 year ago, RHK has about the same amount of shares outstanding.
RHK has about the same amout of shares outstanding than it did 5 years ago.
The debt/assets ratio for RHK has been reduced compared to a year ago.
2.2 Solvency
RHK has an Altman-Z score of 3.07. This indicates that RHK is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 3.07, RHK belongs to the best of the industry, outperforming 81.25% of the companies in the same industry.
RHK has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
RHK's Debt to Equity ratio of 0.09 is amongst the best of the industry. RHK outperforms 96.88% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 3.07 |
ROIC/WACC0.41
WACC6.48%
2.3 Liquidity
A Current Ratio of 2.28 indicates that RHK has no problem at all paying its short term obligations.
The Current ratio of RHK (2.28) is better than 96.88% of its industry peers.
A Quick Ratio of 2.19 indicates that RHK has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.19, RHK belongs to the top of the industry, outperforming 96.88% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.28 | ||
| Quick Ratio | 2.19 |
3. Growth
3.1 Past
RHK shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -15.41%.
The Earnings Per Share has been growing slightly by 0.03% on average over the past years.
Looking at the last year, RHK shows a quite strong growth in Revenue. The Revenue has grown by 9.10% in the last year.
RHK shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 4.12% yearly.
EPS 1Y (TTM)-15.41%
EPS 3Y15.28%
EPS 5Y0.03%
EPS Q2Q%3.33%
Revenue 1Y (TTM)9.1%
Revenue growth 3Y4.41%
Revenue growth 5Y4.12%
Sales Q2Q%8.37%
3.2 Future
Based on estimates for the next years, RHK will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.57% on average per year.
Based on estimates for the next years, RHK will show a small growth in Revenue. The Revenue will grow by 5.93% on average per year.
EPS Next Y4.3%
EPS Next 2Y10.47%
EPS Next 3Y11.09%
EPS Next 5Y11.57%
Revenue Next Year6.74%
Revenue Next 2Y5.36%
Revenue Next 3Y6.5%
Revenue Next 5Y5.93%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 22.63, which indicates a rather expensive current valuation of RHK.
Based on the Price/Earnings ratio, RHK is valued a bit more expensive than 62.50% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 27.25. RHK is around the same levels.
RHK is valuated correctly with a Price/Forward Earnings ratio of 16.88.
Compared to the rest of the industry, the Price/Forward Earnings ratio of RHK is on the same level as its industry peers.
RHK's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 23.98.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.63 | ||
| Fwd PE | 16.88 |
4.2 Price Multiples
96.88% of the companies in the same industry are more expensive than RHK, based on the Enterprise Value to EBITDA ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 0.39 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
PEG (NY)5.26
PEG (5Y)665.51
EPS Next 2Y10.47%
EPS Next 3Y11.09%
5. Dividend
5.1 Amount
RHK has a yearly dividend return of 0.78%, which is pretty low.
RHK's Dividend Yield is comparable with the industry average which is at 1.57.
Compared to an average S&P500 Dividend Yield of 1.92, RHK's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.78% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
RHK pays out 17.78% of its income as dividend. This is a sustainable payout ratio.
DP17.78%
EPS Next 2Y10.47%
EPS Next 3Y11.09%
FRA:RHK (1/9/2026, 7:00:00 PM)
12.9
+0.1 (+0.78%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners0.55%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap863.78M
Revenue(TTM)1.69B
Net Income(TTM)37.68M
Analysts74.29
Price Target14.45 (12.02%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.78% |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP17.78%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-4.43%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.72%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.63 | ||
| Fwd PE | 16.88 | ||
| P/S | 0.52 | ||
| P/FCF | N/A | ||
| P/OCF | 14 | ||
| P/B | 0.66 | ||
| P/tB | 0.77 | ||
| EV/EBITDA | 0.39 |
EPS(TTM)0.57
EY4.42%
EPS(NY)0.76
Fwd EY5.92%
FCF(TTM)-0.12
FCFYN/A
OCF(TTM)0.92
OCFY7.14%
SpS24.7
BVpS19.41
TBVpS16.81
PEG (NY)5.26
PEG (5Y)665.51
Graham Number15.78
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.02% | ||
| ROE | 2.9% | ||
| ROCE | 3.25% | ||
| ROIC | 2.67% | ||
| ROICexc | 4.45% | ||
| ROICexgc | 5.55% | ||
| OM | 2.86% | ||
| PM (TTM) | 2.28% | ||
| GM | 66.81% | ||
| FCFM | N/A |
ROA(3y)2%
ROA(5y)1.56%
ROE(3y)2.83%
ROE(5y)2.2%
ROIC(3y)2.34%
ROIC(5y)2.01%
ROICexc(3y)3.1%
ROICexc(5y)2.62%
ROICexgc(3y)3.7%
ROICexgc(5y)3.13%
ROCE(3y)2.85%
ROCE(5y)2.44%
ROICexgc growth 3Y17.7%
ROICexgc growth 5Y-1.56%
ROICexc growth 3Y17.75%
ROICexc growth 5Y-1.75%
OM growth 3Y11.39%
OM growth 5Y-7.03%
PM growth 3Y10.42%
PM growth 5Y-3.92%
GM growth 3Y-1.4%
GM growth 5Y-0.67%
F-Score6
Asset Turnover0.89
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 1.07 | ||
| Cap/Depr | 112.99% | ||
| Cap/Sales | 4.21% | ||
| Interest Coverage | 14.78 | ||
| Cash Conversion | 56.66% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.28 | ||
| Quick Ratio | 2.19 | ||
| Altman-Z | 3.07 |
F-Score6
WACC6.48%
ROIC/WACC0.41
Cap/Depr(3y)97.27%
Cap/Depr(5y)108.32%
Cap/Sales(3y)4.24%
Cap/Sales(5y)5.08%
Profit Quality(3y)86.55%
Profit Quality(5y)290.53%
High Growth Momentum
Growth
EPS 1Y (TTM)-15.41%
EPS 3Y15.28%
EPS 5Y0.03%
EPS Q2Q%3.33%
EPS Next Y4.3%
EPS Next 2Y10.47%
EPS Next 3Y11.09%
EPS Next 5Y11.57%
Revenue 1Y (TTM)9.1%
Revenue growth 3Y4.41%
Revenue growth 5Y4.12%
Sales Q2Q%8.37%
Revenue Next Year6.74%
Revenue Next 2Y5.36%
Revenue Next 3Y6.5%
Revenue Next 5Y5.93%
EBIT growth 1Y2.05%
EBIT growth 3Y16.29%
EBIT growth 5Y-3.2%
EBIT Next Year147.27%
EBIT Next 3Y44.19%
EBIT Next 5Y27.97%
FCF growth 1Y26.17%
FCF growth 3Y42.66%
FCF growth 5YN/A
OCF growth 1Y42.49%
OCF growth 3Y9.38%
OCF growth 5Y21.95%
RHOEN-KLINIKUM AG / RHK.DE FAQ
Can you provide the ChartMill fundamental rating for RHOEN-KLINIKUM AG?
ChartMill assigns a fundamental rating of 5 / 10 to RHK.DE.
What is the valuation status of RHOEN-KLINIKUM AG (RHK.DE) stock?
ChartMill assigns a valuation rating of 2 / 10 to RHOEN-KLINIKUM AG (RHK.DE). This can be considered as Overvalued.
Can you provide the profitability details for RHOEN-KLINIKUM AG?
RHOEN-KLINIKUM AG (RHK.DE) has a profitability rating of 4 / 10.
Can you provide the financial health for RHK stock?
The financial health rating of RHOEN-KLINIKUM AG (RHK.DE) is 7 / 10.
How sustainable is the dividend of RHOEN-KLINIKUM AG (RHK.DE) stock?
The dividend rating of RHOEN-KLINIKUM AG (RHK.DE) is 2 / 10 and the dividend payout ratio is 17.78%.